Crinetics, a Vertex Pharmaceuticals Company
Independent Medical Education
Request for Proposals

CME Satellite Symposiums at ENDO & IPC 2027: A New Era of Acromegaly management: Updated Clinical Practice Guidelines

I. Background

About Crinetics Pharmaceuticals Independent Medical Education Grants

Crinetics Pharmaceuticals Medical Affairs team supports global independent healthcare initiatives – including research, quality improvement, and education – that address unmet medical needs, improve patient outcomes, and align with our strategic medical and scientific interests.

We sometimes use a Request for Proposal (RFP) process that provides the healthcare community with information on a specific area of interest and the opportunity to apply for grant funding. Appropriate organizations are invited to submit a grant application addressing healthcare gaps as outlined in the RFP.

In compliance with guidelines surrounding industry support of independent medical education, the grant requester (and ultimate recipient) is responsible for designing, managing, and executing the independent project funded by the grant. Crinetics Pharmaceuticals must not be involved in any aspect of an independent medical education activity.

About this RFP

CME Satellite Symposiums at ENDO & IPC 2027: A New Era of Acromegaly Management: Updated Clinical Practice Guidelines

From extensive research, the Crinetics Medical Affairs team considers there to be a knowledge and practice gap in the management of patients with acromegaly. The intent of this RFP is to provide financial support to organizations that have also identified unmet educational needs surrounding the medical management of acromegaly, the new acromegaly consensus guidelines and can develop and execute a CME Satellite Symposiums at the **Endocrine Society's 2027 Annual Meeting** to be held on June 5–7, 2027 in Toronto, ON, Canada (ENDO) & the **20th International Pituitary Congress** to be held on June 2 - 4, 2027 in Toronto, ON, Canada (IPC). Please reach out to ENDO and IPC to learn about their CME satellite symposium process in 2027.

Acromegaly is often misdiagnosed and frequently inadequately managed long-term. The persistent challenge of delayed diagnosis remains a critical issue, with recent data suggesting diagnostic delays of 5-7 years in specialized centers but beyond 10 years in broader clinical settings. While historically considered to

have an incidence of 3-4 cases per million annually, contemporary epidemiological studies suggest the true prevalence potentially reaches 8-13 cases per 100,000 population. This underscores a substantial pool of undiagnosed or misdiagnosed cases.

Recent studies indicate that after diagnosis, nearly 45% of patients remain inadequately controlled on their initial therapy. This treatment gap highlights the importance of endocrinologists updating their current knowledge about acromegaly management. While endocrinologists may only see a handful of acromegaly patients annually, each case requires complex decision-making regarding treatment selection, monitoring, and long-term management. Endocrinologists must consider factors such as efficacy, breakthrough symptoms, the rapidity of IGF-I lowering, absorption variables, compliance challenges, impact on tumor volume, and monitoring requirements when developing long term management plans. Importantly, clinicians should be aware of emerging therapies such as oral therapeutic options, adding yet another layer of complexity to these decisions. The soon to be published updated consensus statement is reshaping the management of acromegaly, particularly its treatment options, including the introduction of newer available therapies with data in both switch and treatment-naive populations. Endocrinologists need to understand which patients may be best suited to the newer therapies, how efficacy and safety data compare, and how to incorporate it into treatment plans. Case-based discussions grounded in the updated consensus statement will offer a practical, real-world approach to managing this complex disease. Keeping endocrinologists informed of the latest recommendations enables evidence-based clinical decision-making and helps ensure that patients receive the most effective, up-to-date care available.

Date of RFP Issue: October 29, 2026

II. Key Information

Due Date for Grant Proposal	**December 11, 2026 5 PM PT**
Medical Specialties	Endocrinologists and other HCPs involved in managing acromegaly
Area of Interest	Our intent is to support an educational symposium at ENDO & IPC 2027 that addresses practice gaps related to: • Knowledge gap that most endocrinologists experience on the most recent acromegaly consensus. What's new and what's changed in acromegaly management. • Case-based application of the most up to date acromegaly guidelines
Global Scope	United States of America
Required Information to be included in Grant Proposal *(not to exceed 10 pages in 11pt Font)*	• **Executive Summary:** Concise overview of the grant proposal • **Needs Assessment:** Defines the existing education or practice gap that the project will address**,** discussing the multiple resources used to derive the gap • **Educational Objectives:** Clearly stated, measurable objectives for the learner • **Methodology:** Technique(s) proposed to close the gap, including enduring materials • **Evaluation Plan:** How will the impact of the intervention be measured? • **Targeted Learners and estimated reach** • **Budget (including Fee for ENDO and IPC).** Provide separate budget for each event. • **Organization Mission and independent medical education experience**

	and accreditations • **Start Date(s) and Timeline** • **W-9 Form / W-8BEN Form**
Grant Amount Range	**Up to $300K for each event**
Key Dates	• RFP released **October 29, 2026** • Grant Application due date: **December 11, 2026 by 5 pm Pacific Time.** • Grant Review Committee review: **Week of January 18, 2027** • Likely Grant Award Notification Date: **On or before January 31, 2027**
Applicant Eligibility	Healthcare institutions can apply for an independent medical education grant to support bonafide educational programs and activities related to disease awareness and improvement of patient care. To be eligible, applicants must be an independent, accredited medical educator that conforms to Food and Drug Administration (FDA) and Accreditation Council for Continuing Medical Education (ACCME) standards.
Grant Agreement	If your application is approved, your organization will need to enter into a written agreement with Crinetics. This RFP is supported by Crinetics Pharmaceuticals and, if approved, grant payment will be sent from the United States.

III. Requirements

How to Apply	Please read this section carefully. Applications that do not follow these instructions will be cancelled. • Go to our **Funding and Support** webpage • Choose **Medical Education Grants**. • Accept the Privacy Policy and hit **Submit.** • Fill out the short **Medical Education Grant Application.** • **Upload a .pdf** of your comprehensive grant proposal (follow the outline as shown above in the section: **Required Information to be included in Grant Proposal** • IMPORTANT: Be advised applications submitted after the due date will not be reviewed.
Questions	If you have questions regarding this RFP, please contact **grants@crinetics.com** with the subject line: RFP **[ENDO & IPC 2027 Acromegaly]**

How grant proposals are reviewed	Grant requests received in response to a specific RFP are reviewed by an internal grant review committee comprising medical, scientific, and legal professionals.
How applicants will be notified	All applicants will be notified via email. Applicants may be asked for additional clarification during the review period.